Treating Cancer Without Compromise

Junny is the President of The Joseph Ahmed Foundation (JAF), a 501(c)3 non-profit organization that was founded in 2016 by the family of Joseph Ahmed, who lost his courageous battle with Ewing’s Sarcoma eight months after his diagnosis on September 1, 2014, at the age of 16. Through their tragic loss and grief, Joseph’s loved ones established the Joseph Ahmed Foundation. Junny and her husband and co-President, Tharwat share more about their mission, resources, and ways to get involved.

On this episode, Thomas Cook takes you into how his "networking brain" works. He talks about how he met the Founder of Tyme, as well as several of the milestones he has shared as a part of the company over the last several years - from fundraising to recruiting board members. Please enjoy the show.

Jonathan Eckard has served as Tyme's Chief Scientific Affairs Officer since 2017 and assumed the role of Chief Business Officer in March 2019. Dr. Eckard has over 12 years of financial experience in equity research, bringing to us both important industry insights and comprehensive understanding of the healthcare equity capital markets. From 2016 to 2017, Dr. Eckard was Chief Business and Strategy Officer of SELLAS Life Science, a private oncology-focused biotechnology company. His previous finance roles include equity research analyst roles at Barclays Capital Markets, Citi Capital Markets, Leerink Swann, and HSBC Securities.In this episode, we get a behind the scenes peek at:- How the concept of SM-88 has evolved.- What makes SM-88 different from other types of cancer therapies?- Why SM-88 offers fewer side effects than common cancer therapies.- How Tyme’s approach may be applicable to a variety of cancers.

Ben Taylor has served as President and Chief Financial Officer of Tyme Inc. since 2017. Ben brings decades of experience in investment banking and emerging growth companies. From 2016 to 2017, Ben was Head of Commercial Pharma for Barclays Capital Inc. Prior to Barclays, Ben spent ten years at Goldman, Sachs & Co., where he held a variety of roles, including Head of Emerging Pharma and Co-Head of Chinese and Southeast Asian Healthcare within the investment banking division. His career has primarily been focused on biopharmaceuticals, working as an advisor to over a hundred companies at various stages of development in more than 15 countries.On this episode, Ben discusses:- Why he left a high profile and secure position on Wall Street to join Tyme's executive team- An inside look at what goes into the development of a drug from a business perspective- Tyme's partnership with PanCAN- Day to day life as the President and CFO of an emerging biotech company

Dr. Giuseppe Del Priore has served as Tyme's Chief Medical Officer since 2016. From 2013 to 2016, Dr. Del Priore served as the National Director of Gynecologic Oncology for Cancer Treatment Centers of America (CTCA). Prior to CTCA, Dr. Del Priore was a Distinguished Tenured Professor at the Indiana University School of Medicine and Cancer Center. He previously also served as faculty and leadership at Montefiore Medical Center, Bellevue Hospital, Cornell and New York University School of Medicine. In today's episode, Dr. Del Priore discusses:- The story of the first patients he ever treated and the impact that had on his career.- What it means to be a Chief Medical Officer at a biotech company.- Some success stories from the TYME-88-Panc and prostate studies.- Why this company is different than anywhere else he has worked.- What is a physician network and how has the physician network grown?

Michele Korfin, RPh, MBA, has served Tyme's Chief Commercial Officer since October 2018 and assumed the role of Chief Operating Officer in March 2019. Michele has over 20 years of experience in oncology, focused on product launches, oncology marketing strategy, commercial sales, market access, and government affairs.In this episode Michele covers some fascinating topics like:The Hill, Congress, and the political side of a biotech company when it comes to patient advocacy.Her previous experiences at Celgene, launching one of the leading cancer drugs.Why Michele decided to join the Tyme team.The FDA, and the regulatory environment and processes.· Patients seeking therapy and how Tyme is working with top cancer centers around the country.Please enjoy the show, and don't forget to rate, share, and review this podcast! We may be making forward looking statements, regarding our operational outlook, as well as our regulatory and product development plans. These statements are subject to risk and uncertainties that may cause actual results to differ from those forecasted. A description of those risks can be found in our most recent 10-K on file with the Securities and Exchange Commission.